Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

March 18, 2025 8:05 AM

Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the treatment of solid tumors. APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB...

Read more

Ankle & Foot Centers of America Offers Advanced Treatment Options for Fungal Toenail Infections

March 18, 2025 8:01 AM

Toenail fungus is one of the rare medical conditions that simultaneously sounds unpleasant but also unserious. For that reason, Ankle & Foot Centers of America cautions that the condition can cause painful complications that may require advanced treatments that its expert podiatrists can provide.Fungal toenail infections, also known as onychomycosis, are common, affecting nearly 10 percent of the U.S. population, and one in two people age 70 or...

Read more

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

March 18, 2025 8:00 AM

SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, announced it will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with experts in the field of pain management. In...

Read more

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

March 18, 2025 7:00 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most Innovative Companies for 2025.Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful...

Read more

Duly Health and Care to Open New Clinic in Schaumburg, Bringing World-Class Care to the Chicago Suburb

March 18, 2025 7:00 AM

Duly Health and Care, through one of its medical groups, will open a new multi-specialty facility in Schaumburg, Ill. this August, the independent medical group brand announced today. The 100,000-square-foot clinic located at 1325 Meacham Road will be the first of its kind in the Chicago suburb."We're thrilled to offer patients in Schaumburg and surrounding areas access to personalized, leading-edge care close to home," said Paul Merrick, MD,...

Read more

Eberbach and Bioz Partner to Deliver Advanced Scientific Validation to Researchers

March 18, 2025 3:00 AM

Bioz, Inc., a pioneer in AI-driven scientific product validation, is proud to expand its partnership with Eberbach Corporation, a trusted provider of precision laboratory mixing equipment. By integrating Bioz Badges across Eberbach's product webpages, researchers can now instantly see peer-reviewed citations showcasing real-world applications of hand motion shakers, as well as reciprocal and orbital shaker lines.This AI-driven integration...

Read more

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025

March 17, 2025 5:15 PM

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2025 were approximately $2.5 million, an...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

March 17, 2025 4:16 PM

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2024."I am very proud of what our team has accomplished this year, and we are excited to unblind the topline data from our XYNGARI™ Phase 3...

Read more

MLD Announces Positive First-in-Human Phase I Results of Its Synthetic Plasmalogen Precursor Drug PPI-1011

March 17, 2025 2:00 PM

Med-Life Discoveries, LP ("MLD", or the "Company"), a biopharmaceutical company dedicated to the development of plasmalogen therapeutics for complex diseases associated with plasmalogen deficiencies, is excited to announce that it has published the first ever Phase I study of a plasmalogen precursor treatment in humans. The Phase I study was completed in Canada and evaluated the safety, tolerability, and pharmacokinetic properties of PPI-1011 in...

Read more

ZetrOZ Systems Shares Recovery Benefits of sam Wearable Ultrasound Unit at Ragin' Cajuns Game

March 17, 2025 9:30 AM

Playing basketball puts enormous stress on tendons and ligaments and can cause sprains, strains, and tendonitis that sideline players. ZetrOZ Systems, inventors of sustained acoustic medicine and the sam® wearable ultrasound unit, recently traveled to the University of Louisiana to attend a basketball game and share its advanced recovery solutions for athletes."Watching the speed and intensity of the Ragin' Cajuns on the court was a great...

Read more

Hypha Laboratories Retains Stockhouse for International Awareness Campaign

March 17, 2025 9:15 AM

Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls™ suite of products, is pleased to announce that the Company has engaged Canada-based financial media giant Stockhouse for market awareness.With over 1 million unique visitors a month, Stockhouse is Canada's #1 financial portal and one of North America's largest small cap investor communities. Its members are smart, affluent investors...

Read more

Med Holdings Group inc's (OTC: YUKA) Subsidiary Company Medsmart Wellness Centers is Proud to Announce That They Have Signed a Letter of Intent to Acquire a State of the Art 3000 Square Foot Facility

March 17, 2025 8:30 AM

MedSmart Wellness Centers Inc., a subsidiary of Med Holdings Group Inc., is proud to announce the signing of a Letter of Intent (LOI) to acquire a state-of-the-art 3,000-square-foot facility located in Tequesta, Florida, between Jupiter, and West Palm Beach. This acquisition marks a significant milestone in the company's expansion and will enhance its ability to provide cutting-edge wellness and healthcare services to the community.The fully...

Read more

Glidian Joins Infinx to Advance Prior Authorization Automation and Expand Market Reach

March 17, 2025 8:00 AM

Infinx, a leader in AI-powered revenue cycle management solutions, announces the acquisition of Glidian, a market leader in prior authorization automation. The strategic move strengthens Infinx's patient access solutions while expanding its footprint in the laboratory market, where Glidian has established itself as a leader.Glidian was founded with the mission of automating prior authorizations to ensure patients receive timely access to...

Read more

Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System

March 17, 2025 7:00 AM

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Monogram mBôs™ TKA System. This determination means that Monogram may market the device, subject to the general controls provisions of the Act.Ben Sexson, Monogram...

Read more

NHI Announces $46.3 Million Senior Housing Investment

March 17, 2025 6:00 AM

National Health Investors, Inc. (NYSE:NHI) announced today that it has invested $46.3 million, inclusive of transaction costs, for the acquisition of Juniper Village at Paramus, a senior housing community in Bergen County, NJ, just outside of New York City. Juniper Village at Paramus, a community with 98 assisted living units and 22 memory care units, has been operated by Juniper Communities, a premier operator of 28 senior housing communities...

Read more

Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

March 17, 2025 3:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with...

Read more

Ondine Biomedical Inc. Announces Quebec Hospital Cuts Spine SSIs by 78%

March 17, 2025 3:00 AM

At the 25th Annual Scientific Conference of the Canadian Spine Society, researchers from the University of Sherbrooke presented findings from a year-long retrospective quality of care study confirming the safety and efficacy of Steriwave® nasal photodisinfection therapy (aPDT) in spine surgery patients. Data from the podium presentation demonstrated that patients who received presurgical Steriwave nasal photodisinfection had 78.8% fewer surgical...

Read more

BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement

March 14, 2025 7:00 PM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce that, further to its news release of February 28, 2025, it has closed the final tranche of its previously announced non‐brokered private placement (the "Offering") of convertible debenture units ("Debenture Units") for gross proceeds of $900,000. The Company issued an aggregate of 5,000,000 Debenture Units for aggregate proceeds of $2,500,000...

Read more

Viromed Medical AG Reports Promising Study Results for PulmoPlas(R) in Intensive Care Unit Ventilator-Associated Pneumonia Patients

March 14, 2025 10:30 AM

Viromed Medical AG ("Viromed", Ticker:VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, wound healing, and intensive care medicine, today announces promising study results for treating ventilator-associated pneumonia (VAP) in intensive care unit (ICU) patients using its cold atmospheric pressure plasma device candidate, PulmoPlas®. VAP is a severe lung...

Read more

Gilead Sciences - Women's History Month Celebrated With Its Team

March 14, 2025 9:55 AM

In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and...

Read more